Synthetic Biologics Inc (SYN) Stock Rating Lowered by ValuEngine
Synthetic Biologics Inc (NYSEMKT:SYN) was downgraded by stock analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued to investors on Friday.
Other research analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Synthetic Biologics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. William Blair restated an “outperform” rating and issued a $5.00 price target on shares of Synthetic Biologics in a research report on Monday, May 22nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $3.92.
Shares of Synthetic Biologics (SYN) opened at 0.75 on Friday. The firm has a 50-day moving average of $0.58 and a 200 day moving average of $0.61. The firm’s market capitalization is $96.19 million. Synthetic Biologics has a 12-month low of $0.41 and a 12-month high of $1.90.
Synthetic Biologics (NYSEMKT:SYN) last issued its quarterly earnings results on Thursday, August 3rd. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.03. On average, equities research analysts expect that Synthetic Biologics will post ($0.17) earnings per share for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Norges Bank bought a new position in Synthetic Biologics during the fourth quarter worth about $356,000. UBS Group AG increased its position in Synthetic Biologics by 10.3% in the first quarter. UBS Group AG now owns 214,357 shares of the company’s stock worth $135,000 after buying an additional 20,038 shares during the last quarter. Bank of New York Mellon Corp increased its position in Synthetic Biologics by 3.1% in the first quarter. Bank of New York Mellon Corp now owns 263,598 shares of the company’s stock worth $166,000 after buying an additional 7,962 shares during the last quarter. Susquehanna International Group LLP increased its position in Synthetic Biologics by 76.4% in the second quarter. Susquehanna International Group LLP now owns 189,342 shares of the company’s stock worth $107,000 after buying an additional 82,030 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in Synthetic Biologics by 8,102.7% in the second quarter. Goldman Sachs Group Inc. now owns 1,129,108 shares of the company’s stock worth $639,000 after buying an additional 1,115,343 shares during the last quarter.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.